Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunocore to present at the Jefferies London Healthcare Conference

11/11/2021 | 07:01am EST

PRESS RELEASE

Immunocore to present at the Jefferies London Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place November 16-19, 2021.

The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. The webcast can also be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com.

##

About Immunocore

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but are not limited to, statements regarding the Company’s business strategy including its proposed regulatory plans for tebentafusp, the efficacy, safety and therapeutic potential of tebentafusp, the expected timing of a BLA review and action date for tebentafusp for the treatment of mUM, the potential approval and commercial launch of tebentafusp for mUM, the design, progress, timing, scope and results of the Company’s clinical trials including IMC-C103C, IMC-F106C, IMC-I109V and IMC-M113V, the anticipated achievement of upcoming clinical milestones, the potential benefit of Breakthrough Therapy Designation or Orphan Drug Designation for tebentafusp, and the Company’s anticipated cash runway. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials; changes in expected or existing competition; changes in the regulatory environment; and the uncertainties and timing of the regulatory approval process. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 25, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.

CONTACT: 

Immunocore
Debra Nielsen, Head of Communications
T: +1 (610) 368-8602
E: debra.nielsen@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com


All news about IMMUNOCORE HOLDINGS PLC
01/27Immunocore Wins US FDA Nod for Skin Cancer Drug
MT
01/26IMMUNOCORE : announces FDA approval of KIMMTRAK« (tebentafusp-tebn) for the treatment of u..
PU
01/26Health Care Stocks Catching Up With Late Market Declines
MT
01/26Health Care Stocks Putting Up Modest Gains
MT
01/26Health Care Stocks Climb Premarket Wednesday
MT
01/26Health Care
MT
01/26Top Premarket Gainers
MT
01/26Immunocore Holdings Says it Gets FDA Approval for Rare Cancer Treatment; Shares Jump Pr..
MT
01/26Immunocore Gets FDA OK of Kimmtrak in Uveal Melanoma
DJ
01/26Immunocore announces FDA approval of KIMMTRAK« (tebentafusp-tebn) for the treatment of ..
GL
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2021 26,0 M 34,9 M 34,9 M
Net income 2021 -127 M -171 M -171 M
Net cash 2021 191 M 256 M 256 M
P/E ratio 2021 -5,22x
Yield 2021 -
Capitalization 679 M 909 M 911 M
EV / Sales 2021 18,8x
EV / Sales 2022 16,5x
Nbr of Employees 291
Free-Float 73,4%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1 549,31 GBX
Average target price 3 557,85 GBX
Spread / Average Target 130%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
David Berman Head-Research & Development
Roy Steven Herbst Non-Executive Director
John Irving Bell Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC-39.43%909
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892